2026-05-07T12:10:34+08:002023-08-02|
Contact Information
Title
Research Assistant Professor
Team Office
(Address) N22-4034 / (Phone) +853 8822 2903
Email
fangyuanshao@um.edu.mo
Consultation Hours

Working days 09:00 – 13:00, 14:30 – 17:45

Teaching
Education
PhD University of Macau, China, 2020
Msc Guangdong Pharmaceutical University, China, 2014
Bsc Huazhong Agricultural University, China, 2011
Position
12/2022 – Present Research Assistant Professor, Faculty of Health Sciences, University of Macau
01/2021 – 01/2023 UM Macao Postdoctoral Fellowship, Faculty of Health Sciences, University of Macau
Research Interests
  1. Multi-drug resistance in the cancer, mechanisms and treatment strategy,
  2. Protein homeostasis,
  3. Anticancer drug and mitochondrial damage
Representative Publications
  1. Y. Shao, X.Y. Lyu, K. Miao, L.S. Xie, H.T. Wang, H. Xiao, Q. Chen, R.B. Ding, P. Chen, F.Q. Xing, X. Zhang, G.H. Luo, W.L. Zhu, G. Cheng, N.W. Lon, S.E. Martin, G.Y. Wang, G.K. Chen, Y.L. Dai, C.X. Deng, Enhanced protein damage clearance induces broad drug resistance in multi-type of cancers revealed by an evolution drug resistant model and genome-wide siRNA screening, Advanced Science (2020). 5 year IF: 15.6 First author
  2. Fangyuan Shao, Zongjie Li, Hao Xiao, Yujun Chen, Yuheng Zhang, Ling Li, Yuzhong Peng, Xinyi Li, Yuxing Hou, Bo Li, Xiangpeng Chu, Maoxin Ran, Dongyang Tang, Xi Han, Jiaxin Yao, Cuiting Zhang, Lijian Wang, Haifeng Li, Nan Shao, Kai Miao, Xiaoling Xu, Yanxia Shi, Changhua Zhang, Jun Yan, Ying Lin, and Chu-Xia Deng, Suppressing Protein Damage Response to Overcome Multidrug Resistance in Cancer Therapy, Cell Discovery (2025). 5 year IF: 14.3 First author
  3. Shao, Z. Li, M. Ran, Y. Chen, J. Liu, B. Li, M. Hong, Q. Si, X. Ye, X. Chu, Y. Hou, E. Cheung, K.Y. Tam, H. Xiao, G.FUpdat, X. Xu, C.X. Deng, Low dose radiation induces new protein synthesis that promotes cancer radiotherapy resistance, Drug Resist Updat, 86 (2026). 5 year IF: 23.0, First author and co-corresponding author
  4. Fangyuan Shao, Dongyang Tang, Ling Li, Xiaoling Xu, and Chu-Xia Deng. Recent progresses in cancer multidrug resistance and therapeutic options associated with protein damage response. Protein & Cell, accepted (in press), (2026) 5 year IF: 19.5, First author.
  5. Chen, F. Shao, J. Zeng, S. Guo, L. Wang, H. Sun, J.H. Lei, X. Lyu, S. Gao, Q. Chen, K. Miao, X. Xu, C.X. Deng, Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling, Sci Adv, 9 (2023) eabq1395. 5 year IF: 14.1
  6. Li, Y. Feng, J. Zhou, F. Shao, Y. Peng, S. Zang, J.H. Lei, H. Sun, D. Tang, S. Lin, J. Chen, H. Li, X. Chu, Y. Qiao, X. Guo, K. Wu, X. Xu, C.X. Deng, Proteasomes suppress anticancer drug-induced cytotoxicity by inhibiting mitochondrial protein import and promoting ROS-BNIP3-mediated mitophagy, Drug Resistance Updates, 83 (2025) 101294. 5 year IF: 23.0
  7. Tang, S. Lin, J. Zhou, J.H. Lei, F. Shao, H. Sun, X. Chu, L. Li, L. He, Y. Qiao, X. Xu, C.X. Deng, Augment proteasome inhibitor efficacy activates CD8(+) T cell-mediated antitumor immunity in breast cancer, Cell Rep Med, 6 (2025) 102211. 5 year IF: 11.7
  8. Miao, A. Zhang, X. Yang, Y. Zhang, A. Lin, L. Wang, X. Zhang, H. Sun, J. Xu, J. Zhang, Y. Feng, F. Shao, S. Guo, Z. Weng, P. Luo, D. Wang, S. Gao, X.-Y. Zhao, X. Xu, C.-X. Deng, Lymphatic system is the mainstream for breast cancer dissemination and metastasis revealed by single-cell lineage tracing, Mol Cancer, 24 (2025). IF: 33.9
  9. Li, H. Chen, S. Yang, F. Chen, L. Xu, Y. Li, M. Li, C. Zhu, F. Shao, X. Zhang, C. Deng, L. Zeng, Y. He, C. Zhang, Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers, Mol Cancer, 22 (2023) 71. IF: 33.9
  10. Xue, T. Wang, J. Yao, W. Wu, D. Chen, B. Yan, X. Dong, Y. Tang, Y. Zeng, Y. He, P. Cao, F. Shao, W. Huang, C. Deng, J. Yan, Use of patient-derived tumor organoid platform to predict the benefit of postoperative adjuvant chemotherapy for poor responders to neoadjuvant chemoradiotherapy in locally advanced rectal cancer, Bioeng Transl Med, 8 (2023) e10586. IF: 5.7
  11. Wang, S. Guo, S.J. Kim, F.Y. Shao, J.W.K. Ho, K.U. Wong, Z. Miao, D. Hao, M. Zhao, J. Xu, J. Zeng, K.H. Wong, L. Di, A.H. Wong, X. Xu, C.X. Deng, Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel, Theranostics, 11 (2021) 2442-2459. IF: 13.3
  12. Miao, J.H. Lei, M.V. Valecha, A. Zhang, J. Xu, L. Wang, X. Lyu, S. Chen, Z. Miao, X. Zhang, S.M. Su, F. Y. Shao, B.K. Rajendran, J. Bao, J. Zeng, H. Sun, P. Chen, K. Tan, Q. Chen, K.H. Wong, X. Xu, C.X. Deng, NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation, Nature Communication, 11 (2020) 3256. IF: 15.7
  13. Xiao, C. Zha, F.Y. Shao, L. Wang, B. Tan, Amino acids regulate energy utilization through mammalian target of rapamycin complex 1 and adenosine monophosphate activated protein kinase pathway in porcine enterocytes, Anim Nutr, 6 (2020) 98-106. IF: 7.5
  14. Zheng, F.Y. Shao, S. Martin, X. Xu, C.X. Deng, WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance, Sci Rep, 7 (2017) 43517. IF: 3.9
  15. Y. Shao, H. Sun, C.X. Deng, Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype, Oncotarget, 8 (2017) 73329-73344. IF: 4.8 First author
  16. Xiao, F.Y. Shao, M. Wu, W. Ren, X. Xiong, B. Tan, Y. Yin, The application of antimicrobial peptides as growth and health promoters for swine, J Anim Sci Biotechnol, 6 (2015) 19. IF: 6.5 Co-first author
  17. Wang, F.Y. Shao, Z. Liu, J. Zhang, S. Wang, J. Liu, H. Liu, H. Chen, K. Liu, M. Xia, Y. Wang, The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-kappaB and disruption of mitochondria-dependent pathways, Chem Biol Interact, 205 (2013) 1-10. IF: 5.4 Co-first author
Research Grants
10/2022 – 09/2025 Department of Science and Technology of Guangdong Province (GDSTC) (2022A1515110671)
Mechanism study of bortezomib to overcome multi-drug resistance in the breast cancer.
06/2023 – 01/2024 Ministry of Education Frontiers Science Centre for Precision Oncology, University of Macau (SP2023-00001-FSCPO)
Identification of mitochondrial protein damage response genes to overcome multidrug resistance
01/2023 – 12/2024 Seventh Affiliated Hospital of Sun Yat-sen University, Open Fund of Guangdong Provincial Key Laboratory of Digestive Cancer Research (GPKLDCR202207M)
Mechanism study of drug induced protein damage in the digestive system malignancy for clinical usage of the proteasome activity detection kit
Patents
  1. 邓初夏, 邵方元, 彭宗根，李虎，一种缓冲液、试剂盒和蛋白酶体检测方法，中国专利，发明专利， 202211119256.5，申请日:2022-08-27
  2.  邓初夏, 邵方元, 卡非佐米在制备治疗抗药肿瘤的药物中的新的应用，中国专利，发明专利， 202011126326.0，申请日:2020-11-12
  3.  邓初夏, 邵方元, NEW APPLICATION OF CARFILZOMIB IN A PREPARATION OF DRUGS FOR A TREATMENT OF DRUG-RESISTANT TUMORS，国外专利，发明专利，63112168，申请日:2020-11-12